synthesis, labeling, formulation and quality control of 99mtc-tricine-hynic-tyr³-octreotide, a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [persian]
Authors
abstract
somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. in this study tyr³-octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-boc-hydrazinopyridine-3-carboxylic acid (boc-hynic) and after deprotecting of conjugate, purification was performed with preparative-rp-hplc. the conjugated peptide was labeled with 99mtc and tricine as coligand. radiolabelling efficiency, radiochemical purity, stability in human serum, internalization of receptor bound 99mtc-labeled peptide and biodistribution in normal mice were studied.
similar resources
Synthesis, labeling, formulation and quality control of 99mTc-Tricine-HYNIC-Tyr³-Octreotide, a peptide radiopharmaceutical for imaging Somatostatin receptor positive tumors [Persian]
Somatostatin analoges labeled with different radionuclides are able used for imaging and treatment of somatostatin receptor positive tumors. In this study Tyr³-Octreotide protected at lysine as an analoge of somatostatin was conjugated with bifunctional chelating agent 6-BOC-hydrazinopyridine-3-carboxylic acid (BOC-HYNIC) and after deprotecting of conjugate, purification was performed wit...
full textPreparation, formulation and quality control of one step kit 99mTc- EDDA/HYNIC-Tyr3-Octreotide as a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [Persian]
The high expression of somatostatin receptors in many tumours, have made receptor scintigraphy with 111In-DTPA-Octreotide a widly used procedure in nuclear medicine. Despite its clinical success, some limitation and drawbacks of radiolabelling with 111In remain, especially those concerned with the cost, availability and physical decay properties of this radionuclide. 99mTc-EDDA/HYNIC-Tyr3...
full textpreparation, formulation and quality control of one step kit 99mtc- edda/hynic-tyr3-octreotide as a peptide radiopharmaceutical for imaging somatostatin receptor positive tumors [persian]
the high expression of somatostatin receptors in many tumours, have made receptor scintigraphy with 111in-dtpa-octreotide a widly used procedure in nuclear medicine. despite its clinical success, some limitation and drawbacks of radiolabelling with 111in remain, especially those concerned with the cost, availability and physical decay properties of this radionuclide. 99mtc-edda/hynic-tyr3-toc w...
full textevaluation and comparison of different quality control methods in radiochemical purity determination of new peptide kits 99mtc-edda-tricine-hynic-tyr3-octreotide and 99mtc-edda-tricine-hynic-tyr3-octreotate for imaging somatostatin receptor positive tumors [persian]
introduction: using labeled peptides enjoys high importance in nuclear medicine. somatostatin analogs labeled with different radionuclide are vastly investigated for diagnosis or treatment of somatostatin receptor positive tumors. labeling somatostatin analogs with 99mtc as alternative of 111in needs doing different quality control method for determination of labeling yield and complex stabilit...
full textA 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging
Melanocortin-1 (MC1) receptor is an attractive melanoma-specific target for the development of α-MSH peptide based imaging and therapeutic agents. In this work a new lactam bridge α-MSH analogue was synthesized and radiolabeled with 99mTc via HYNIC chelator and tricine as co-ligand. Also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude m...
full textA 99mTc-tricine-HYNIC-labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging
Melanocortin-1 (MC1) receptor is an attractive melanoma-specific target for the development of α-MSH peptide based imaging and therapeutic agents. In this work a new lactam bridge α-MSH analogue was synthesized and radiolabeled with 99mTc via HYNIC chelator and tricine as co-ligand. Also, stability in human serum, receptor bound internalization and tissue biodistribution in tumor bearing nude m...
full textMy Resources
Save resource for easier access later
Journal title:
iranian journal of nuclear medicinePublisher: tehran university of medical sciences
ISSN 1681-2824
volume 11
issue 1 2003
Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023